论文部分内容阅读
为了研究吉非替尼对中、晚期非小细胞肺癌(NSCLC)患者血清基质金属蛋白酶-7(MMP-7)、血清基质金属蛋白酶-9(MMP-9)表达的影响。本研究选取2014年9月至2015年8月本院收治的60例中、晚期NSCLC患者,根据随机数表法分为对照组30例和实验组30例。所有患者均采取营养、镇痛等对症支持治疗,对照组在此基础上采用GP方案,在第1~3天静脉滴注25 mg/m~2的顺铂,在第1天、第8天静脉滴注1 000 mg/m~2的吉西他滨;实验组在对症支持治疗基础上予以吉非替尼,口服,250 mg/次,1次/d,所有患者均以4周为1个治疗周期。观察患者治疗前和治疗1个周期后MMP-7、MMP-9表达情况,两组患者的不良反应率与临床疗效之间比较。通过治疗分析后,实验组的临床疗效率显著高于对照组,93.33%(28/30)比70.00%(21/30)(p<0.05)。实验组的血清MMP-7、MMP-9表达显著低于对照组,(0.27±0.07)ng/m L比(0.64±0.04)ng/m L,(270.92±30.24)ng/m L比(335.88±31.01)ng/m L(p<0.05)。实验组的不良反应率显著低于对照组,6.67%(2/30)比30.00%(9/30)(p<0.05)。研究结果表明在治疗中、晚期NSCLC患者中,吉非替尼能明显降低MMP-7、MMP-9的表达,临床疗效显著,安全性高。
To investigate the effect of gefitinib on the serum levels of matrix metalloproteinase-7 (MMP-7) and serum matrix metalloproteinase-9 (MMP-9) in patients with advanced non-small cell lung cancer (NSCLC) In this study, 60 patients with advanced NSCLC admitted to our hospital from September 2014 to August 2015 were divided into control group (n = 30) and experimental group (n = 30) according to random number table. All patients were treated with symptomatic nutrition such as nourishment and analgesia. On the basis of GP regimen, the control group received intravenous infusion of 25 mg / m ~ 2 of cisplatin on days 1 to 3 on day 1, day 8 Gemcitabine 1 000 mg / m ~ 2 was intravenously instilled. The experimental group was treated with gefitinib on the basis of symptomatic and supportive therapy, orally, 250 mg / time, once a day, all patients were treated with 4 weeks as a treatment cycle . The expression of MMP-7 and MMP-9 in the patients before and after one cycle of treatment was observed. The adverse reaction rate and clinical efficacy of the two groups were compared. After treatment analysis, the clinical efficacy of experimental group was significantly higher than the control group, 93.33% (28/30) than 70.00% (21/30) (p <0.05). The expression of MMP-7 and MMP-9 in the experimental group was significantly lower than that in the control group (0.27 ± 0.07) ng / m L (0.64 ± 0.04) ng / m L and (270.92 ± 30.24) ng / m L ± 31.01) ng / m L (p <0.05). The rate of adverse reactions in the experimental group was significantly lower than that in the control group, 6.67% (2/30) vs. 30.00% (9/30) (p <0.05). The results show that in the treatment of advanced NSCLC patients, gefitinib can significantly reduce the expression of MMP-7, MMP-9, with significant clinical efficacy and safety.